Afamelanotide

Mechanism (as reported)

Research described afamelanotide as an α-MSH analogue that binds/activates melanocortin-1 receptor (MC1R) signaling to increase melanin synthesis and modulate inflammation (PMIDs: 33507118, 28063031).

Key findings (each cites a source)

• A review of afamelanotide in EPP reported that clinical studies in EPP showed increased exposure to sunlight and improved quality of life, and described it as acting on melanocortin-1 receptors (PMID: 33507118). [PMID 33507118]
• A review stated that afamelanotide is a synthetic α-melanocyte–stimulating hormone analogue and first-in-class melanocortin-1 receptor agonist approved in the EU for prevention of phototoxicity in adults with EPP (PMID: 26979527). [PMID 26979527]
• In two multicenter randomized, double-blind, placebo-controlled trials in EPP, afamelanotide was associated with longer duration of pain-free direct sunlight exposure and improved quality of life versus placebo (PMID: 26132941). [PMID 26132941]
• In the CUV039 phase III trial (as described in a review), afamelanotide improved light tolerance, increased time spent in direct sunlight without pain, and increased the time to first symptoms of phototoxicity versus placebo (PMID: 26979527). [PMID 26979527]
• The EPP trials described in one report found quality of life improved with afamelanotide therapy and that adverse events were mostly mild, with serious adverse events not thought to be related to study drug (PMID: 26132941). [PMID 26132941]
• A review focused on broader dermatologic applications stated that the literature search identified RCT evidence for successful use of afamelanotide beyond EPP, including polymorphic light eruption and vitiligo, and reported smaller studies in other dermatologic conditions (PMID: 33683075). [PMID 33683075]
• A pharmacokinetics/pharmacodynamics review reported that afamelanotide binds to the melanocortin-1 receptor (MC1R) and that MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes, and modulates inflammation (PMID: 28063031). [PMID 28063031]
• The pharmacokinetics/pharmacodynamics review described that subcutaneous application had full bioavailability in volunteer studies, whereas oral or transdermal routes did not result in measurable plasma concentrations or a measurable pigmentation response (PMID: 28063031). [PMID 28063031]
• A pharmacokinetics/pharmacodynamics review reported that a controlled-release formulation optimizes administration in humans and is effective at a lower dose than daily saline injections in volunteer studies (PMID: 28063031). [PMID 28063031]